icometrix is pleased to announce that it has signed a new contract with a leading pharmaceutical company for a seven year multicentric non-interventional study. The CE-marked and FDA-cleared icobrain software to be used in the study allows to accurately detect changes on brain MRI scans and is already a part of routine clinical practice worldwide. As the icobrain software is used both in clinical routine and in trials, it uniquely allows the direct comparison of real world results with clinical trial findings, leading to an increasing number of pharmaceutical studies to choose icobrain to monitor the safety and efficacy of disease modifying drugs for neurological disorders.
The new real world study will involve patients from over 100 sites in 16 countries. The icobrain software will be used to longitudinally evaluate MRI scans of approximately 1000 patients with multiple sclerosis. Endpoints of the study include brain volume, number and volume of new and total FLAIR lesion load as well as new Gadolinium enhanced lesions.
The minimal measurement error of the icometrix solution allows the detection of small brain changes over time, yielding important information about disease progression in individual patients. A detailed understanding of changes in subtle brain anomalies in individual people with MS is essential for personalised care and (changes in) therapeutic intervention.
icometrix (Leuven, Belgium; Chicago, IL, USA) is the world leader in software solutions to obtain clinically meaningful data from brain MRI scans. The fully automated icobrain software is FDA approved, and today, it is part of routine clinical practice in hospitals in Europe, Japan, India, Canada, Brazil and Australia. Furthermore, icometrix works with the largest health tech and pharmaceutical companies on the evaluation of trials of drugs for neurological diseases.Back to news